| Identification | Back Directory | [Name]
Tetrapeptide-30 | [CAS]
1036207-61-0 | [Synonyms]
Tetrapeptide-30
Teterapeptide-30
H-Pro-Lys-Glu-Lys-OH
L-Lysine, L-prolyl-L-lysyl-L-α-glutamyl-
Tetrapeptide-30 (skin lightening peptide)
(S)-6-Amino-2-((S)-2-((S)-6-amino-2-((S)-pyrrolidine-2-carboxamido)hexanamido)-4-carboxybutanamido)hexanoic acid | [EINECS(EC#)]
-0 | [Molecular Formula]
C22 H40 N6 O7 | [MDL Number]
MFCD32706887 | [MOL File]
1036207-61-0.mol | [Molecular Weight]
500.59 |
| Chemical Properties | Back Directory | [Boiling point ]
931.5±65.0 °C(Predicted) | [density ]
1.256±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C, protect from light, stored under nitrogen | [form ]
Solid | [pka]
3.24±0.10(Predicted) | [color ]
White to off-white | [Cosmetics Ingredients Functions]
SKIN CONDITIONING
SKIN PROTECTING | [InChIKey]
LYHZXMVNRVAAJA-PEFLOIOHNA-N | [SMILES]
[C@@H](CCCCN)(NC([C@H]1NCCC1)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)O)CCCCN |&1:0,8,17,26,r| |
| Hazard Information | Back Directory | [Description]
Tetrapeptide-30 is a skin-brightening peptide consisting of four amino acids. It can act as a tyrosinase inhibitor, lightening hyperpigmentation and evening out skin tone by reducing the amount of tyrosinase and inhibiting melanocyte activation. | [Uses]
Tetrapeptide-30 is a skin-brightening peptide consisting of four amino acids. Tetrapeptide-30 can act as a tyrosinase inhibitor, lightening hyperpigmentation and evening out skin tone by reducing the amount of tyrosinase and inhibiting melanocyte activation[1]. | [Application]
Light skin freckle, reduce melanin
overproduction, reduce melanin deposition, can be added to skin care
products, such as skin cream, skin foundation, powder, freckle cream
(sunburn, freckles). | [References]
[1] Alessandra Marini, et al. Modulation of skin pigmentation by the tetrapeptide PKEK: in vitro and in vivo evidence for skin whitening effects. Exp Dermatol. 2012 Feb;21(2):140-6. DOI:10.1111/j.1600-0625.2011.01415.x
[2] Reinhard H H Neubert, et al. Dermal peptide delivery using enhancer moleculs and colloidal carrier systems. Part II: Tetrapeptide PKEK. Eur J Pharm Biopharm. 2018 Mar;124:28-33. DOI:10.1016/j.ejpb.2017.12.004 |
|
|